AVTX
NASDAQ · Biotechnology
Avalo Therapeutics Inc
$18.48
-0.81 (-4.20%)
Financial Highlights (FY 2026)
Revenue
228.1K
Net Income
-302,601,754
Gross Margin
100.0%
Profit Margin
-132,642.4%
Rev Growth
-85.2%
D/E Ratio
0.03
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 58.1% | 58.1% |
| Operating Margin | -123,601.7% | -111,241.5% | 21.6% | 19.4% |
| Profit Margin | -132,642.4% | -126,010.3% | 22.3% | 22.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 228.1K | 1.54M | 36.29M | 36.66M |
| Gross Profit | 228.1K | 1.54M | 21.09M | 21.30M |
| Operating Income | -281,887,250 | -1,709,558,793 | 7.82M | 7.11M |
| Net Income | -302,601,754 | -1,835,185,839 | 8.09M | 8.22M |
| Gross Margin | 100.0% | 100.0% | 58.1% | 58.1% |
| Operating Margin | -123,601.7% | -111,241.5% | 21.6% | 19.4% |
| Profit Margin | -132,642.4% | -126,010.3% | 22.3% | 22.4% |
| Rev Growth | -85.2% | -85.2% | +16.8% | -1.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 12.65M | 12.65M | 45.39M | 52.32M |
| Total Equity | 451.77M | 451.77M | 96.06M | 95.40M |
| D/E Ratio | 0.03 | 0.03 | 0.47 | 0.55 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -280,645,620 | -1,796,585,842 | 9.50M | 9.77M |
| Free Cash Flow | — | — | 4.67M | 3.24M |